Identification of a Dual-Specific T Cell Epitope of the Hemagglutinin Antigen of an H5 Avian Influenza Virus in Chickens by Haghighi, HR et al.
Identification of a Dual-Specific T Cell Epitope of the
Hemagglutinin Antigen of an H5 Avian Influenza Virus in
Chickens
Hamid R. Haghighi1., Leah R. Read1., S. M. Mansour Haeryfar2, Shahriar Behboudi3, Shayan Sharif1*
1Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada, 2Department of Microbiology and Immunology, The University of Western Ontario,
London, Ontario, Canada, 3 Institute of Hepatology, University College London, London, United Kingdom
Abstract
Avian influenza viruses (AIV) of the H5N1 subtype have caused morbidity and mortality in humans. Although some
migratory birds constitute the natural reservoir for this virus, chickens may play a role in transmission of the virus to
humans. Despite the importance of avian species in transmission of AIV H5N1 to humans, very little is known about host
immune system interactions with this virus in these species. The objective of the present study was to identify putative
T cell epitopes of the hemagglutinin (HA) antigen of an H5 AIV in chickens. Using an overlapping peptide library covering
the HA protein, we identified a 15-mer peptide, H5246–260, within the HA1 domain which induced activation of T cells in
chickens immunized against the HA antigen of an H5 virus. Furthermore, H5246–260 epitope was found to be presented by
both major histocompatibility complex (MHC) class I and II molecules, leading to activation of CD4+ and CD8+ T cell subsets,
marked by proliferation and expression of interferon (IFN)-c by both of these cell subsets as well as the expression of
granzyme A by CD8+ T cells. This is the first report of a T cell epitope of AIV recognized by chicken T cells. Furthermore, this
study extends the previous finding of the existence of dual-specific epitopes in other species to chickens. Taken together,
these results elucidate some of the mechanisms of immune response to AIV in chickens and provide a platform for creation
of rational vaccines against AIV in this species.
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Introduction
Avian influenza virus (AIV) is a type A influenza virus, which
belongs to the family of enveloped RNA viruses. AIV genome
encodes 11 proteins, among which hemagglutinin (HA) and
neuraminidase (NA), are two surface antigens that are used to
classify influenza viruses [1]. Birds are the natural hosts of AIV;
however, infection in mammals, including humans can also occur
by influenza viruses originating from avian hosts [2].
Immunity to influenza viruses is a concerted effort of both
innate and adaptive responses.
In this regard, T cell-mediated immune responses play a critical
role in defense against influenza infection [3]. A number of studies
using mouse models have shown the induction of virus-specific
CD8+ T cells following infection with influenza virus, and have
underscored the important role of these cells in protection against
influenza [4,5]. CD4+ T cells also play a part in immunity against
influenza. In fact, CD4+ T cells are induced following influenza
virus infection and have a central role in immunity via the
induction and maintenance of CD8+ T cell memory, and
providing help to B cells for antibody production [6–8].
Numerous T cell epitopes from various proteins of influenza
virus have been identified in human and mouse [9]. A number of
studies have also been conducted to reveal the immunogenicity
and protective effect of several of these epitopes. For example,
epitopes derived from nucleoprotein (NP), polymerase acidic (PA)
and M proteins of influenza virus induced strong specific cytotoxic
T cell response [10–13].
Despite extensive research conducted on immune responses
against influenza in mammals, our understanding of immunity,
especially T cell responses, against influenza virus in chickens is
very limited. It is known that AIV surface proteins including HA
and NA are able to induce neutralizing antibodies in chickens and
these antibodies play a role in protection against highly pathogenic
avian influenza viruses (HPAI) [14]. The protective role of CD8+
T cells in AIV infection has also been shown [15]. It was
demonstrated that depletion of CD8+ T cells in immunized birds
resulted in abrogation of immunity against a challenge with a
highly pathogenic H5N1 AIV [15]. Seo and Webster [16] have
also shown that chickens immunized with the H9N2 subtype are
protected against H5N1 AIV, indicating the effective recognition
of the internal components of the virus by cells of the immune
system. Interestingly, these birds mount a cross-reactive cytotoxic
T lymphocyte (CTL) response and upon transfer of T cells from
protected birds, naı¨ve recipients become protected against
challenge with virulent H5N1 virus [16]. The antigen specificity
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of these T cells is unknown. In fact, there is no information about
MHC class I and class II-restricted epitopes of AIV recognized
by chicken T cells. Furthermore, the effector responses of chicken
T cells against AIV have not been fully elucidated, however, it has
recently been shown that AIV infection induces up-regulation of
cytokines such as IFN-c [17].
The HA protein is known to be the most protective antigen of
influenza virus [18–20] and has been used as a target antigen for a
number of influenza vaccines in humans and animals [21–23].
Over 150 B cell epitopes as well as 113 CD4+ T cell and 35 CD8+
T cell epitopes have been identified within this antigen [9] and
some of these epitopes have been shown to induce immune
response and confer protection in humans [24,25], mice [26], and
rabbits [27]. However, there is no information available on
epitopes of HA, or any other AIV proteins, that are recognized by
chicken T cells. Therefore, in the present study, we sought to
identify T cell epitopes of the HA protein of an H5 AIV in
chickens. To our knowledge, this is the first report that describes a
T cell epitope of AIV in avian species.
Materials and Methods
Chickens and Housing
Fertile SPF eggs were obtained from the genetically-defined line
P2a (homozygous for the B19 haplotype) (Cornell University,
Ithaca, NY, USA). This chicken line was used, because these
chickens are homozygous for the B19 MHC haplotype and,
moreover, we had developed reagents for this particular MHC
haplotype. All birds were maintained in Horsfall units within an
isolation unit. This research was approved by the University of
Guelph Animal Care Committee and complied with the guidelines
of the Canadian Council on Animal Care.
Recombinant Vaccine
The TROVAC
TM
-AIV H5 vaccine was kindly provided by
Merial (Merial Select Inc, Gainesville, GA, USA). This vaccine is a
recombinant fowlpox virus vector that expresses the HA antigen of
the isolate A/turkey/Ireland/1378/83 (H5N8).
Peptide Library
A library of 112 overlapping peptides, covering the entire HA
protein encoded by the TROVACTM-AIV H5 vaccine virus, was
synthesized by Mimotopes (Clayton, Australia). Peptides were 15
residues long and overlapped by 10 residues. Peptide pools were
prepared at 10 peptides per pool for a total of 12 pools (pools 11
and 12 had 6 peptides per pool). For subsequent experiments,
peptides were synthesized at a purity of 90% and suspended to
2.25 mM using the solvent recommended by the manufacturer.
Purity of peptides was confirmed by mass spectrometry.
Experimental Design
P2a chickens were vaccinated with TROVACTM-AIV H5 (or
received vaccine diluent) at 14 days of age and received the
secondary immunization on day 21 of age, at the dose recom-
mended by the manufacturer. At 10 or 21 days post-secondary
immunization, spleens were harvested and mononuclear cells
prepared for in vitro stimulation with peptides. Following in vitro
stimulation, cells were analyzed for indicators of cell activation
either by assessment of tritiated thymidine incorporation or cytokine
expression. MHC restriction of potential T-cell epitopes was
assessed by blocking with anti-MHC or anti-CD4/anti-CD8
antibodies. Alternately, mononuclear cells were sorted into CD4+
and CD8+ subsets and cell proliferation was measured in the
presence of irradiated antigen presenting cells and the cognate
peptide. In both experiments, cell proliferation was measured by
assessment of tritiated thymidine incorporation. Cytokine expres-
sion was also measured in CD4+ and CD8+ subsets sorted after
exposure to the stimulatory peptide or the control treatment.
Single Cell Suspension of Spleen and Separation of
Mononuclear Cells
Spleen mononuclear cells were isolated as previously described
[28]. Following isolation, cells were suspended in FACS buffer (1%
bovine serum albumin in PBS) or complete RMPI cell culture
medium.
In Vitro Stimulation of Spleen Cells Using Peptide Pools
and Individual Peptides
The initial screening of peptide pools was done on day 10 and day
21 post-secondary vaccination. In two replicate experiments,
mononuclear cells were prepared from pools of three spleens from
each of control and vaccinated birds. Cells were suspended in cell
culture medium and peptide pools were added to a final
concentration of 1.0 or 10 mM (per peptide). The peptides in pool
5 were screened individually at 1 mM and 10 mM in 3 replicates of
pooled splenocytes from 3 vaccinated birds. The stimulatory peptide
within pool 5 was titrated to determine a dose response, by addition
of 0.1 mM through 20 mM of the peptide in replicate experiments
using spleen cells from 4 individual vaccinated birds. Spleen cells
were also treated with concanavalin A (ConA) (Sigma Aldrich, St.
Louis, Mo) at 20 mg/ml (positive control), or with peptide solvent or
medium as negative controls. Following addition of peptide or
control treatments, cells were incubated at 41u C for 24, 48 or
72 hours. Eighteen hours before the end of each timepoint, 1 mCi of
methyl-3H-thymidine, 25 Ci/mmol (GE Healthcare, Baie d’Urfe,
Quebec) was added to each well. Plates were frozen at280uC until
processed. Cells were harvested onto glass fibre filters and thymidine
incorporation was measured using the TopCount NXT Microplate
Scintillation Counter (Packard/PerkinElmer, Waltham, Massachu-
setts, USA). Results are presented as stimulation index (SI) which is
the mean cpm of treatment culture divided by the mean cpm of
control cultures. SI values .3 for both concentrations of peptides
were considered significant.
Determination of MHC Restriction of T Cell Responses to
the Putative Epitope
To determine MHC restriction of the response to the stimulatory
peptide, spleen mononuclear cells from vaccinated birds (in 3
replicate experiments) were isolated and treated with the following
antibodies: mouse anti-chicken MHC Class I and Class II, anti-
CD4 and anti-CD8 antibodies or isotype control at a final
concentration of 5 mg/ml for 90 minutes, before the addition of
peptide (1 mM), or control treatments. Cells were incubated for
72 hours with an 18 hour pulse of methyl-3H-thymidine. All
monoclonal antibodies were mouse anti-chicken and included anti-
MHC II (EP25, IgG1, kindly provided by Dr. Michael Ratcliffe),
anti-MHC I (clone F21-2, IgG1), anti-CD4, (clone CT-4, IgG1),
anti-CD8a, (clone CT8, IgG1) and the isotype control (mouse IgG1)
(all from Southern Biotech, Birmingham, Alabama).
Fluorescent-Activated Cell Sorting (FACS) and Magnetic-
Activated Cell Sorting (MACS)
For sorting, 66107 cells from vaccinated birds were double
stained with mouse anti-chicken CD4-RPE and mouse anti-
chicken CD8a-chain-FITC. FACS controls (16106 cells), included
unstained cells and cells stained with either mouse anti-CD4-RPE,
mouse anti-CD8a-chain-FITC or appropriate isotype controls. All
Epitopes of H5N1 Viruses
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antibodies were used at a concentration of 100 ng per 16106 cells
in 100 ml. After staining, the labeled cells were immediately sorted
using the FACSAria instrument (BD Biosciences, Franklin Lakes,
NJ, USA) and used in the antigen presentation assay or used for
RNA extraction.
In 3 replicate experiments, CD8+ and CD4+ spleen cells were
magnetically sorted from vaccinated birds using the MACS system
(Miltenyi Biotech, Auburn, California, USA). Spleen mononuclear
cells (26108) were cultured for 24 hours with the peptide H5246–260,
or the peptide solvent. Cells were split, washed in FACS buffer and
labeled with mouse anti-chicken CD4 or mouse anti-chicken CD8a-
chain (Southern Biotech, Birmingham, Alabama) in separate tubes,
followed by a secondary staining with goat anti-mouse IgG
microbeads (Miltenyi Biotech, Auburn, California, USA). RNA
was extracted from sorted cell subsets.
Preparation of Antigen Presenting Cells (APCs)
Mononuclear cells from the spleen of a vaccinated bird were
prepared as the source of APCs. Cells were briefly pulsed with
peptide before irradiation. Peptide (10 mM) or peptide solvent was
added to 16108 cells and cell suspensions were incubated for
1 hour at 41u C in a humidified incubator. Cells were then
irradiated with 30 Gy of gamma irradiation using a T780C Cobalt
60 radiation therapy treatment unit (Theratronics International,
Kanata, Ontario).
Antigen Presentation Assay
In two replicate experiments using three individual vaccinated
birds, peptide-pulsed or non-pulsed APCs (16106 cells or 26105
cells in 50 ml) were mixed with CD4+ or CD8+ sorted splenocytes
(16105 cells per 100 ml) to give an APC to responder ratio of either
10:1 or 2:1. Negative controls included sorted cells alone, with or
without peptide (10 mM), or with ConA. Cell proliferation was
measured at 72 hours.
Gene Expression in Peptide-Stimulated Spleen Cells
Expression of interferon (IFN)- c, interleukin (IL)-10, granzyme
A and perforin mRNA was examined in spleen cells after
stimulation with peptide. Spleen mononuclear cells of three
control and five vaccinated birds were treated with peptide
(10 mM), ConA or medium, and harvested at 2, 8, 16, and
24 hours post-stimulation for extraction of RNA. Total RNA
from spleen mononuclear cells was extracted as described pre-
viously [29].
In a separate experiment, splenocytes from three vaccinated
birds were stimulated for 24 hours with peptide (10 mM). Cells
were stained with anti-CD4/anti-CD8 as described above and
sorted into CD4+ and CD8+ subsets using MACS and RNA
extracted using RNeasyH Micro extraction kit (Qiagen, Mis-
sissauga, Ontario).
A total of 1 mg of RNA was reverse transcribed to cDNA with
oligo(dT)12–18 primers using the Superscript First-Strand cDNA
Synthesis kit (Invitrogen Corporation, Carlsbad, CA, USA).
Primers, plasmid calibrator constructs and standard curves for
real-time PCR were produced, as previously described [29,30,31],
for b-actin, IL-10, IFN-c, granzyme A, and perforin. To quantify
the relative expression of cytokines, 10-fold diluted cDNA was
used as the template for real-time PCR, using b-actin as the
reference gene. The samples were amplified in 384-well plates
using the LightcyclerH 480, or in glass capillaries using the
LightcyclerH 2.0 (Roche Diagnostics GmbH, Mannheim, Ger-
many) using reagents and conditions as previously described
[29,31].
Data Analysis
Real-time PCR data was analyzed using REST-MCS [32] to
calculate the relative fold-change in gene expression between
control and peptide stimulated samples. The data were normalized
using the reference gene, b-actin, and are corrected for PCR
efficiencies. PCR efficiencies were calculated previously
[29,30,31]. The statistical significance level was set at p#0.05.
Sequence Analysis
Influenza virus sequences were obtained from GenBank and
aligned with H5246–260 using NCBI BLAST. H5246–260 was
compared to H5 sequences from strains of avian hosts (H5N1,
H5N2, H5N3, H5N8 and H5N9) and avian/human hosts
(H5N1). In addition, homology of H5246–260 with other hemag-
glutinin subtypes including strains of avian hosts (H1N1), avian/
human hosts (H2N2), human hosts (H3N2), swine hosts (H3N2)
and avian/human/swine hosts (H1N1) were examined.
The ‘‘Epitope Prediction’’ function of SYFPEITHI (http://
www.syfpeithi.de/) was used to predict the HLA alleles that could
bind to H5246–260. HLA alleles with a score of .15 are reported.
Results
Screening of the HA Peptide Library
Spleen cells from chickens vaccinated with TROVACTM-AIV
H5 consistently showed the highest proliferation in response to
peptide pool 5 compared to other peptide pools and cells from
sham immunized chickens. This response was observed at both 10
and 21 days post-secondary immunization and at peptide
concentrations of 1.0 and 10 mM. (Figure 1a). To identify the
cognate peptides, individual peptides within pool 5 were screened
for activity. Peptide H5246–260, which is located in the HA1
domain of the HA protein, induced greater cell proliferation
compared to other peptides within the same pool or compared to
controls (Figure 1b), suggesting that H5246–260 was the reacting
peptide within this pool. The results were confirmed in
independent experiments performed on different days. Titration
of the stimulatory peptide revealed that spleen mononuclear cell
stimulation occurred over a wide range of peptide concentrations,
although in some of the experiments, using peptides at 10 mM
induced a slightly higher level of proliferation in spleen cells
(Figure 1c). Cell proliferation induced by H5246–260 was not a non-
specific stimulation because cells from sham vaccinated birds did
not proliferate in response to this peptide (data not shown). There
was also a weak response to pool 7, but because it was not
consistently present in both experimental replicates. Furthermore,
the individual peptides within this pool did not display any
stimulatory activities (data not shown). Therefore, this pool and its
peptides were not examined any further.
Cytokine Expression in Cells Stimulated with H5246–260
Peptide
To further examine the recognition of H5246–260 peptide by T
cells, the expression of IFN-c and IL-10 genes was measured. IFN-c
and IL-10 were selected to represent the activation of CD4+ T
helper (Th)1/CD8+ T cytotoxic (Tc)1 and regulatory T cells (Treg),
respectively. IFN-c expression was found to be higher in splenocytes
stimulated with the identified peptide compared to untreated spleen
cells. IFN-c was significantly upregulated at 2, 8 and 16 hours post-
stimulation compared to cells that were not treated with the peptide
(p,0.001–0.05), whereas IL-10 expression was not significantly
different between control and peptide stimulated cells. (Figure 2a,b).
These findings suggest that Th1 or Tc1 cells, but not Treg, are
activated by peptide stimulation.
Epitopes of H5N1 Viruses
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Figure 1. Identification of stimulatory peptide pools and individual peptides. P2a chickens were vaccinated with TROVAC
TM
-AIV H5 or
vaccine diluent. (1a) In two replicate experiments, at days 10 and 21 post-secondary vaccination, spleen mononuclear cells from control and
vaccinated chickens were pooled and used for peptide screening. A peptide library covering the entire HA antigen of an H5 virus was used in 12
pools. Cells were stimulated with peptide pools at concentrations of 1.0 and 10 mM for 24, 48 or 72 hours. (1b) Peptides from pool 5 of the peptide
library were used individually at day 21 post-secondary vaccination to stimulate spleen mononuclear cells of vaccinated P2a chickens. In each of three
replicate experiments, cells from vaccinated birds were stimulated using peptide for 48 or 72 hours. (1c) Spleen mononuclear cells from vaccinated
birds in 4 independent replicates were used to determine dose-dependent proliferative response to H5246–260. Cells were incubated with peptide or
peptide solvent for 72 hours. For all figures, cell proliferation, as measured by average stimulation index, (mean cpm of treatment/mean cpm of
peptide solvent cultures for all independent experimental replicates), is shown for spleen mononuclear cells harvested at 21 days post-secondary
vaccination and cultured for 72 hours. SI values .3 for both concentrations of peptides were considered significant.
doi:10.1371/journal.pone.0007772.g001
Figure 2. Cytokine mRNA expression in splenocytes in response to H5246–260. In three replicate experiments, spleen mononuclear cells from
vaccinated birds were incubated with peptide or peptide solvent for 24 hours before RNA extraction and cytokine analysis using real-time PCR.
Relative expression of IFN-c (A), IL-10 (B) mRNA normalized to b-actin expression in stimulated and unstimulated spleen mononuclear cells are
presented. Comparisons were made using the REST program and considered significant at P#0.05 (*).
doi:10.1371/journal.pone.0007772.g002
Epitopes of H5N1 Viruses
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Determination of MHC Restriction Using Antibody
Blocking
To examine MHC restriction of H5246–260 peptide, blocking
experiments were conducted using antibodies against chicken
CD4, CD8, MHC class I and class II. Using antibodies against
MHC I and MHC II a reduction in cell proliferation in response
to H5246–260 was noticed. Similar results were obtained in
antibody blocking experiments using anti-CD4 and anti-CD8a
antibodies (Figure 3a,b). Therefore, the peptide appeared to be
presented to T cells via both MHC class I and II molecules.
Activation of T Cell Subsets by H5246–260 Peptide-Pulsed
APCs
To show that CD4 and CD8 T cell subsets can both recognize
H5246–260 peptide presented by antigen presenting cells, CD4+
and CD8+ T cells were purified and stimulated in vitro with the
cognate peptide. Stimulation of purified CD4+ or CD8+ T cells
with the peptide-pulsed gamma-irradiated APCs resulted in a
significant proliferation of both T cell subsets (Figure 4a,b). Also,
when irradiated APCs alone were stimulated with the peptide in
the absence T cells, no proliferation was observed (data not
shown). These results confirm the stimulatory ability of H5246–260
peptide for both T cell subsets.
Gene Expression in T Cell Subsets in Response to
H5246–260 Peptide
T cell subsets were sorted after 24 hours of peptide stimulation
and cytokine expression was determined in CD4+ or CD8+ T
cells. Relative expression of both IFN-c and IL-10 mRNA was
significantly increased in both CD4+ and CD8+ subsets stimulated
with H5246–260 peptide when compared to controls which received
no peptide (p#0.05) (Figure 5). There was also a significant
(p#0.05) increase in expression of granzyme A in CD8+ T cells
stimulated with the peptide compared to the untreated cells.
Expression of perforin was also slightly upregulated in the peptide-
stimulated CD8+ T cells, although the difference between treated
and control cells did not reach statistical significance (Figure 6).
Sequence Analysis of H5246–260 Peptide
Peptide H5246–260 shared similarity with corresponding domains
in other influenza viruses, including H5, H2N2, H3N2 and H1N1
viruses in the range of 46%-100% (Table 1). Based on peptide-
binding motifs of the HLA alleles deposited in the SYFPEITHI
database, H5246–260 is predicted to bind to HLA-A*01, A*0201,
A*03, B*08, B*3902, and B*5101 as well as HLA-DRB1*0101,
DRB1*0301, DRB1*0401, DRB1*0701, DRB*1501.
Discussion
The main objective of the present study was to identify T cell
epitopes of the HA antigen of an H5 AIV in chickens. Using a
peptide library covering the full length of the HA protein, we
found a 15-mer peptide that was able to induce T cell proliferation
and IFN-gamma expression in chickens immunized with a
fowlpox virus-based vaccine expressing the H5 protein. Our data
suggest that this peptide was presented by both MHC class I and II
molecules, leading to activation of CD4+ and CD8+ T cell subsets.
The importance of these findings is two fold. First, this is the first
study to identify an immunodominant T cell epitope of AIV in
chickens and, second, the H5 epitope identified here has the
capacity to stimulate both T cell subsets. Vaccination with dual-
specific epitopes may be more efficacious than a mixture of CTL
and Th cell epitopes, as they could allow CD4+ and CD8+ cells to
interact with the same APC, thereby improving communication
between cells [33].
In this study, we used a recombinant FPV-based vaccine
expressing AIV-H5 from A/turkey/Ireland/1378/83 (H5N8).
This vaccine has been shown to elicit antibody responses and
protect chickens against a challenge with HPAI viruses [22,18].
Here, we present evidence that this vaccine elicits T cell responses
to the HA antigen in chickens.
Several T cell epitopes have already been identified for almost
all proteins encoded by influenza A viruses in mouse and human.
More specifically, close to 150 T cell epitopes, most of which are
CD4+ T cell epitopes, have been identified within the HA antigen
of different influenza virus subtypes [9]. In the present study,
Figure 3. Determination of MHC restriction of response to H5246–260. Antibodies against MHC I and MHC II (A) and anti-CD4 and anti-CD8 (B)
were used to block proliferative response to peptide, H5246–260. In at least 5 replicate experiments, spleen mononuclear cells from vaccinated birds
were incubated with 5 mg/ml antibodies or isotype control before addition of peptide or solvent control. There were two additional groups of control
cells, one being treated with the peptide without addition of any antibodies (peptide alone) and the second being treated with peptide solvent
without addition of any antibodies (solvent alone). Proliferation was measured at 72 hours. Data are presented as counts per minute and error bars
represent standard errors of the mean.
doi:10.1371/journal.pone.0007772.g003
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following screening 112 peptides covering the entire length of the
HA protein, we identified a peptide epitope, H5246–260, that elicited
T cell proliferation and cytokine production. The H5246–260 peptide
is located in the H1 region of HA and although its location does not
contain receptor-binding sites of HA [34], it does constitute a
glycosylation site.
The H5246–260 epitope is partially conserved (.86% similarity)
among several H5 viruses. For example, A/Hong Kong/156/97
and A/Viet Nam/1194/2004 H5N1 viruses contain sequences
within the same region of HA that are only different from the
H5246–260 peptide by two residues at positions 7 and 9. Moreover,
within the H5246–260 peptide, there are certain motifs that also
Figure 5. Cytokine mRNA expression in CD4+ and CD8+ T cell subsets. Spleen mononuclear cells from vaccinated birds in three replicate
experiments, were co-cultured with peptide solvent or peptide, H5246–260 (10 mM) for 24 hours followed by magnetic cell sorting into CD4+ and CD8+
T cell subsets. Sorted cells were used for RNA extraction and cytokine analysis using real-time PCR of cDNA. Relative expression of IFN-c (A), IL-10 (B)
mRNA normalized to b-actin in CD4+ and CD8+ T cells treated with the peptide or peptide solvent are presented. Comparisons between peptide-
treated and control cells were made using the REST program and considered significant at P#0.05 (*).
doi:10.1371/journal.pone.0007772.g005
Figure 4. Proliferative response to H5246–260 in sorted CD4+ and CD8+ spleen cells. Spleen mononuclear cells from vaccinated birds, in 6
replicate experiments, were sorted into CD4+ and CD8+ T cell subsets followed by co-culture with APC and peptide, H5246–260 (10 mM) at an APC to
responder ratio of either 2:1 or 10:1. T cell subsets were also cultured with or without the peptide in the absence APC (no APC). In another control
group (APC alone), APCs were cultured in the absence or presence of the peptide. Proliferative response was measured at 72 hours. Results for CD4+
(A) and CD8+ (B) are presented as an average stimulation index, (mean cpm of treatment/mean of control for all independent experimental
replicates).
doi:10.1371/journal.pone.0007772.g004
Epitopes of H5N1 Viruses
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appear to be conserved among other subtypes of influenza virus.
For example, this epitope has sequence identity in the range of
53–66% with H1N1 viruses, 60% with H2N2 viruses and 46–53%
with H3N1 viruses (9 and Table 1), despite the fact that HA is
highly variable among influenza virus subtypes. A peptide epitope,
IYWTIVKPGDILLINS, in this same region of HA of an
H3N2 virus has been identified which is recognized by CD4+ T
cells of individuals with HLA-DRB1*0701 or HLA-DRB1*0101
Figure 6. Granzyme A and perforin mRNA expression in CD8+ T cell subsets. Spleen cells from vaccinated birds in three replicate
experiments, were co-cultured with peptide solvent or peptide, H5246–260 (10 mM) for 24 hours followed by magnetic cell sorting into CD4+ and CD8+
T cell subsets. Sorted cells were used for RNA extraction and cytokine analysis using real-time PCR. Relative expression of granzyme A (A), perforin (B)
mRNA expression normalized to b-actin in CD4+ and CD8+ T cells treated with the peptide or peptide solvent are presented. Comparisons between
peptide-treated and control cells were made using the REST program and considered significant at P#0.05 (*).
doi:10.1371/journal.pone.0007772.g006
Table 1. Sequence Alignment of B7 peptide from HA of A/turkey/Ireland/1378/83 (H5N8) subtype with the corresponding
peptides derived from HA of other influenza virus subtypes.
Peptide sequence Virus strain Subtype Host Similarity
WTILKPSDTINFESN A/turkey/Ireland/1378/83 H5N8 Avian 100%
WTILKPSDTINFESN A/duck/Ireland/113/1983 H5N8 Avian 100%
WTILKPNDAINFESN A/turkey/England/50-92/91 H5N1 Avian 86%
WTILKPNDAINFESN A/goose/Hong Kong/23/1978 H5N3 Avian 86%
WTILKPKDAINFESN A/duck/Hong Kong/342/1978 H5N2 Avian 86%
WTILKPNDAINFESN A/duck/Hokkaido/Vac-1/04 H5N1 Avian 86%
WTILKPNDAINFESN A/Viet Nam/1194/2004 H5N1 Human,
Avian
86%
WTILKPNDAINFESN A/Hong Kong/156/97 H5N1 Human 86%
WTLLDQGDTITFEAT A/chicken/Hong Kong/14/1976 H1N1 Avian 53%
WTLLEPGDTIIFEAN A/Texas/22/1990 H1N1 Human 66%
WTLLDQGDTITFEAT A/mallard/Alberta/35/1976 H1N1 Human,
Avian,
swine
53%
WTLLDMWDTINFEST A/Japan/305/57 H2N2 Human,
Avian
60%
WTLLDMWDTINFEST A/Korea/426/1968 H2N2 Human 60%
WTIVKPGDILLINST A/Aichi/68/2007 H3N2 Human 46%
WTIVKPGDILLINST A/New York/232/2004 H3N2 Human 46%
WTIVKPGDILLINSN A/Port Chlamers/73 H3N2 Human 53%
WTIVKPGDVLVINSN A/Human/Hong Kong/1/68 H3N2 Human 53%
WTIVKPGDVLVINSN A/England/42/72 H3N2 Human 53%
Bold-faced residues represent differences in the sequence of corresponding peptides compared to H5246–260.
doi:10.1371/journal.pone.0007772.t001
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haplotypes [25,9]. Although this remains a speculation, it is possible
that the epitope identified in this study can elicit a T cell response
against influenza viruses of other subtypes. Roti and colleagues [35]
have already demonstrated that human subjects that were exposed
to H1N1 and H3N2 viruses had cross-reactive CD4+ T cell
responses to the HA antigen of A/Viet Nam/1203/2004 (H5N1).
Although there is no empirical evidence available, based on our
analysis of anchor residues of H5246–260 and peptide-binding
motifs of various HLA class I and class II alleles, H5246–260 may be
able to bind several HLA alleles. These observations raise the
possibility of using H5246–260 as a potential epitope for inclusion in
future vaccines against H5N1 in chickens, and possibly for
humans. However, this needs to be confirmed experimentally.
Despite the fact that the peptide library used in the present
study covered the entire HA sequence, only one peptide pool was
found to induce proliferation of cells in a consistent manner. Also,
within this pool, only one peptide was shown to be stimulatory for
T cells of vaccinated birds, suggesting that the identified peptide is
an immunodominant epitope. This observation may indicate the
narrow scope of chicken T cell responses to the HA antigen. An
alternative, but not mutually exclusive scenario is that this may be
a line-specific observation. Bennink and Yewdell [36] have
reported that in mice carrying the H-2k or H-2d MHC haplotypes,
CTLs can recognize HA only when it is presented in the context of
Kk and Kd, but not when presented by MHC class I D and L
molecules. It is important to note that chickens have two MHC-I
and MHC-II genes, the so-called major and minor genes, among
which only the major genes are predominantly expressed [37].
This perhaps imposes some limitations on the repertoire of
peptides recognized by chicken T cells.
The H5246–260 epitope was able to induce both CD4+ and
CD8+ T cell responses. This induction was specific because the
peptide had no stimulatory effect on cells of sham vaccinated birds
and, moreover, the response was completely or partially blocked
by antibodies against MHC-I, MHC-II, CD4, and CD8. In
addition, both purified CD4+ and CD8+ cells responded to the
peptide when it was presented to them by APCs, although APCs
alone were not stimulated with the peptide. Presence of epitopes of
infectious agents and cancer antigens with dual specificity for both
CD4+ and CD8+ T cell subsets has previously been reported by us
and others (38–43). In the context of cancer, dual specificity T cell
epitopes have been identified for alpha-fetoprotein, NY-ESO-1,
and carcinoembryonic antigens [38,39,40,41]. Shams and col-
leagues (2004) discovered a 15-mer peptide (CFP1071–85) of the
culture filtrate protein antigen of Mycobacterium tuberculosis that
could induce production of IFN-c by CD4+ T cells and CTL
activity by CD8+ T cells. Furthermore, this peptide exhibited
promiscuity in that it interacted with T cells of individuals with
several different MHC genotypes [33]. A similar phenomenon has
been observed for some of the epitopes of lymphocytic
choriomeningitis virus, malaria, and HIV [40,42,43]. Dual specific
epitopes have also been identified in influenza virus antigens. For
instance, HA252–271 of influenza virus A/JAPAN/305/57 (H2N2),
which is recognized by CTLs restricted to mouse H-2Kk is also
recognized by CD4+ T cells restricted to I-Ad [44]. Interestingly,
this peptide overlaps with the peptide (H5246–260) that we have
identified in the present study. The observation that H5246–260 can
activate both T cell subsets has some implications for the use of
this epitope as a candidate vaccine against AIV in chickens.
Taken together, we have identified, for the first time, a dual
specific epitope within the HA antigen of an H5 avian influenza
virus, which is recognized by both CD4+ and CD8+ T cell subsets
of chickens vaccinated against H5 protein. Our findings raise the
possibility of using this epitope as a potential vaccine against H5
AIV in chickens. In fact, studies are now underway to assess the
protective efficacy of the H5246–260 epitope in B19 as well as in
non-B19 chickens.
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